abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Osteoporosis management in hematologic stem cell transplant recipients: Executive summary

Author

J Bone Oncol. 2021 Apr 23;28:100361. doi: 10.1016/j.jbo.2021.100361.eCollection 2021 Jun.

D L Kendler 1J J Body 2M L Brandi 3R Broady 4J Cannata-Andia 5M J Cannata-Ortiz 6A El Maghraoui 7G Guglielmi 8P Hadji 9D D Pierroz 10T J de Villiers 11P R Ebeling 12R Rizzoli 13

Author Information

1 Department of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, Canada.

2 CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.

3 Mineral and Bone Metabolic Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

4 Department of Medicine, Division of Hematology, University of British Columbia, Vancouver, Canada.

5 Servicio de Metabolismo Óseo y Mineral, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.

6 Haematology Department, Hospital de la Princesa, IIS Princesa, Madrid, Spain.

7 Rheumatology Department, Military Hospital Mohammed V, Mohammed V-Souissi University, Rabat, Morocco.

8 Department of Radiology, University of Foggia, Foggia, Italy.

9 Frankfurt Center of Bone Health, Frankfurt/Main, Germany.

10 International Osteoporosis Foundation (IOF), Nyon, Switzerland.

11 Department of Gynaecology, Faculty of Health Sciences, Stellenbosch University and Mediclinic Panorama, Cape Town, South Africa.

12 Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Australia.

13 Division of Bone Diseases, Geneva University Hospitals & Faculty of Medicine, Geneva, Switzerland.

Abstract

Background: Treatment advances have reduced the adverse events associated with hematopoietic stem cell transplant (HSCT) and led to an increased number of transplants performed. HSCT patients are living longer with concerns on long-term outcomes. Bone fragility and fracture are at the forefront for long-term morbidities post-HSCT.

Results: In HSCT recipients, evidence has accumulated to support recommendations for more extensive monitoring of bone fragility and more appropriate administration of osteoporosis pharmacotherapies for patients at high risk of bone loss and/or fracture.

Conclusion: This executive summary reports and summarizes the main recommendations published previously, including bone assessment, dietary and lifestyle recommendations and osteoporosis medication.